EB病毒（EBV）感染十分广泛，并与鼻咽癌及淋巴瘤等恶性肿瘤发病密切相关。目前，尚无特异方法防治EBV所致的感染及其相关肿瘤，基于单克隆抗体的分子靶向治疗是当前肿瘤治疗研究中最具前景的新手段，但毒副作用大，稳定性差及体内清除过快等问题限制了其广泛应用。亲和体(affibdoy)分子来源于葡萄球菌蛋白A(SPA)，具备以高亲和力与特定蛋白分子结合的特性，同时因穿透性强、稳定性好和易于制备等诸多优点，在肿瘤治疗方面比单克隆抗体更具优势。本研究拟通过基因工程手段和噬菌体展示技术，筛选EBV潜伏膜蛋白2（LMP2）特异性affibdoy分子，并制备特异性affibdoy分子携带细菌毒素的重组蛋白（affitoxin）,进一步通过体内外实验验证EBV LMP2的affitoxin对鼻咽癌的分子靶向结合和治疗作用。为发展基于LMP2亲和体的EBV感染相关肿瘤的特异性靶向治疗提供新途径，应用前景广阔。

Epstein-Barr virus (EBV) infection is very wide and is closely related to the pathogenesis of tumors such as nasopharyngeal carcinoma and lymphoma. Till to now, there is no specific approach to combating EBV infection and its related tumors.Molecular targeted therapies based on monoclonal antibody is the most promising new way for tumor therapy. However, the problems such as its side effects, poor stability and in vivo clearance quickly limited its wider application. Affibody molecules derived from staphylococcal protein A (SPA), has the characteristics of high affinity bingding with specific protein molecules, and also has strong penetrating, good stability and easy to prepare. Therfore, there are more advantages than monoclonal antibodies in cancer targeting therapy. In this study, we intend to screen the EBV LMP2 specific affibody molecules by using genetic engineering and phage display technology, and prepare the specific affibody molecules recombinant protein with bacterial toxins (affitoxin), to test and verify its specific binding and targeting to nasopharyngeal cancer cells in vitro and in vivo. The study may provide a new way for the specific targeting therapy to tumors assiociated with EBV infection, and have a great application prospects.